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Background: Inter- and intra-subject variability of oral busulfan (Bu)
absorption from the gastrointestinal tract may contribute to busulfan
overexposure, resulting in unfavorable post-transplant adverse events
i.e. veno-occlusive disease. Intravenous (IV) Bu helps to circumvent
this problem by decreasing variability in drug exposure. However,
inter-subject variability of Bu exposure still exists due to differences in
Bu clearance. This multi-institutional, prospective Phase 2 study exam-
ined if pharmacokinetic (PK) modeling based upon a small test dose
prior to the preparative regimen can provide optimized dosing of IVBu.
Methods: Patients with chemo-sensitive relapsed or primary-refrac-
tory lymphoma undergoing a first autologous hematopoietic stem
cell transplantation received a test dose of IV Bu (0.8 mg/kg) given as
a 2 hour continuous infusion on a day between Days -14 and -11. Bu
exposure was determined as area under the concentration-time curve
(AUC) using six whole blood samples obtained at defined intervals after
the end of the infusion. Based on test PK, the remaining Bu dose was
calculated to achieve a total AUC of 20,000 mM$min. One-fourth of
this dose was given as a 3 hour infusion on Day -8, during which a sec-
ond PK analysis was done.The same daily Bu dose was administered on
Days -7, -6, and -5 unless Day -8 PK results showed total AUC outside
the target6 20%. Etoposide 1400mg/m2 was administered onDay -4,
followed by cyclophosphamide 2.5 g/m2/day on Days -3 and -2.
Results: A total of 145 subjects with non-Hodgkin’s (n 5 96) and
Hodgkin’s lymphoma (n 5 49) were enrolled from 32 centers in
the US and Canada. This analysis includes 137 subjects who had
both test PK and Day -8 PK. 52 (38%) patients required dose alter-
ation as a result of test PK. 47 (34.3%) patients required a dose in-
crease, whereas 5 (3.6 %) required a dose decrease. These 52
subjects would have been dosed outside the total target AUC range
during conditioning if test PKwas not performed. The test PK accu-
rately predicted the Day -8 PK. Based on Day -8 PK, only 5 (3.6%)
patients required dose adjustment on Days -6 and -5.
Table. Bu Exposure from Test PK and Day -8 PK
Patient Patient PatientS246Number
(% and 95% CI)Number
(% and 95% CI)Number
(% and 95% CI)AUC (mMmin) < 1000 1000-1500 > 1500
Test PK from
0.8 mg/kgn 5 47 (34.3%,
26.8-42.6)n 5 85 (62.0%,
53.7-69.7)n 5 5 (3.6%,
1.3-8.5)AUC (mMmin) < 16, 000 16, 000-24, 000 > 24, 000
Day -8 PK from
Individual dosesn 5 3 (2.18%,
0.7-6.2)n 5 132 (96.4%,
51.5-98.6)n 5 2
(1.45%, 0.4-5.2)Conclusion: A pretransplant test PK of IV Bu is feasible in a multi-
institutional setting, provides optimized dosing during the condition-
ing regimen and prevents the Bu overexposure or underexposure that
would have occurred in over a third of patients. Intra-patient changes
in Bu clearance between test dose and conditioning dose are minimal.
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BUSULFAN, CYCLOPHOSPHAMIDE, ETOPOSIDE (BUCYVP) OR CARMUS-
TINE, ETOPOSIDE, CYTARABINE, MELPHELAN (BEAM) FOR CONDITION-
ING PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN
PATIENTS WITH HODGKIN LYMPHOMA (HL)?
Salem, G., Ruppert, A.S., Efebera, Y., Elder, P., Bingman, A., Penza, S.,
Andritsos, L.A., Devine, S.M. The Ohio State University James Compre-
hensive Cancer Center, Columbus, OH
Introduction: Busulfan (Bu) based conditioning regimens were devel-
oped for use in ASCT for HLwith the goal to reduce the risk of relapse
without increasing toxicity incomparison tomoreconventional regimens
such asBEAM.AtOhioState, Buwas combinedwith cyclophosphamide
(CY) andVP-16 (BUCYVP) and became the standard conditioning reg-
imen here for 15 years. In 2005, we switched to the BEAM regimen.
Methods: We retrospectively analyzed 188 patients with HL who
underwent ASCT between 1990 and 2010. Cumulative incidence
of relapse (CIR) was measured from transplant date until relapse,
treating deaths as competing risks using Gray’s method. Among pa-
tients with adequate follow-up, proportions of early deaths were
compared using Fisher’s exact test. In relapsed patients, survival
was measured from relapse date until death from any cause.
Results:Median age at transplant was 33 years with 60% of patients
male. Prior to ASCT, 64% received BUCYVP and 36% received
BEAM. Median follow-up among patients relapse-free and alive
was 109 and 16 months, respectively for BUCYVP and BEAM pa-
tients. Those receiving BUCYVPhad higher CIR compared to those
receiving BEAM, approaching statistical significance (p 5 0.06).
When controlling for response status at transplant (p 5 0.03) and
number of prior chemotherapy lines, conditioning regimen did not
predict risk of relapse (p5 0.11; HR5 1.5, 95% CI: 0.9-2.6). How-
ever, 5% and 8% of BUCYVP patients suffered from non-relapse
mortality at 6 and 12 months, respectively, compared to 0 of 67 and
0 of 48 BEAM patients (p 5 0.06 at 12 months). Of 79 relapsed pa-
tients, estimatedmedian survival was 16.5months andwas not differ-
ent between conditioning regimens (p 5 0.96).
Conclusion: Although treatment period differed and more BUCYVP
patients were refractory (39% versus 16%), our experience in HL does
not support that more stringent Bu-based conditioning offers advan-
tages comparedwith BEAMand in factmay be significantlymore toxic.
Table. Cumulative Incidence of Relapse Estimates in Presence
of Competing Risks
All Patients BUCYVP BEAM P crudeCIR N 5 188 N 5 120 N 5 68 (P adjusted)Median (months) Not Reached 50 Not Reached 0.06 (0.11)% relapsed (95% CI)at 12 months 26 (20-33) 29 (21-38) 20 (10-30)at 18 months 36 (29-43) 39 (31-48) 28 (15-40)at 24 months 39 (31-46) 43 (34-52) 28 (15-40)116
PHASE I/II STUDY OF VELCADE®-BEAM (V-BEAM) AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED
INDOLENT NON-HODGKIN’S LYMPHOMA (NHL), TRANSFORMED OR
MANTLE CELL LYMPHOMA (MCL)
William, B.M., Allen, M.S., Loberiza, F.R., Bociek, R.G., Bierman, P.J.,
Armitage, J.O.,Vose, J.M.University ofNebraskaMedical Center,Omaha,NE
A phase I/II trial was designed to evaluate the safety and activity of
adding bortezomib to standard BEAM (BCNU, etoposide,
Poster Session I S247cytarabine, melphalan) and ASCT. Eligible patients (pts) had re-
lapsed/refractory indolent or transformed NHL or MCL that was
relapsed/refractory or in first partial (PR1) or complete remission
(CR1). Pts received bortezomib on D-11, -8, -5, and -2 before
ASCT. Phase I had 4 dose cohorts (0.8, 1, 1.3, and 1.5 mg/m2)
and 3 pts were accrued to each. Any non-hematological ASCT-re-
lated toxicity . 2 on the Bearman scale occurring between D-11
and engraftment defined the maximum tolerated dose (MTD).
Once the MTD has been reached, another 20 pts were enrolled at
this dose to determine a preliminary overall response rate (ORR).
Pts who were in CR or PR at D+100 were considered responders.
The study enrolled 42 pts until 8/14/2009. The median age was 58
(34-73) years; with 33 males and 9 females. The commonest diagnoses
were MCL (23 pts) and FL (7 pts). The median number of prior ther-
apies was 1 (0-6). The median follow-up was 36 (12-55) months. 13 pts
were treated in phase I and 29 pts in phase II. The MTD was initially
determined to be 1.5 mg/m2 but it was later decreased to 1 mg/m2 be-
cause of excessive GI toxicity and peripheral neuropathy (PN). ORR
was 91% at 100 days and 87% at 1 year (y). For all 38 evaluable pts at
1y, responses were CR 84%, PR 3%, and progressive disease 13%.
Progression-free survival (PFS) was 83% (95% CI of 68-92%) at 1y,
and 60% (41-75%) at 3y. Overall survival (OS) was 93% (95% CI
79-98%) at 1y and 80% (62-90%) at 3y. The commonest NCI grade
3 toxicities were neutropenic fever (20), infection (11), anorexia (9),
PN (7), hypotension (6), hypokalemia (5), syncope (5), and 1 pt had
a grade 4 prolonged neutropenia. Compared to 23 MCL in CR1 his-
toric controls treated with BEAM and ASCT, ORR was 85% in the
BEAM group vs. 96% for the V-BEAM group (p 5 0.54). PFS was
85% (64-94%) vs. 85% (65-96%) at 1y and 70% (46-84%) vs.73%
(49-87%) at 3y (log- rank p50.71) for BEAMvsV-BEAMrespectively.
OS was 88% (68-96%) vs. 96% (73-99%) at 1y and 84% (62-94%) vs.
80% (55-92%) at 3y (log-rank p 5 0.74) for BEAM vs. V-BEAM
respectively. Toxicities were comparable between groups except for
some excess of neutropenic fever and PN in the V-BEAM group.
In conclusion, the addition of bortezomib to standard BEAM
(V-BEAM) and ASCT is feasible. Determining relative efficacy of
V-BEAM compared to BEAM would require a randomized trial.117
PHASE II TRIAL OF INTRAVENOUSLY ADMINISTERED AMD3100 (PLERIX-
AFOR) FOR STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE
MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
FOLLOWING A LENALIDOMIDE BASED INITIAL THERAPY
Kumar, S.1, Mikhael, J.2, Lacy, M.1, LaPlant, B.1, Buadi, F.1,
Dingli, D.1, Gertz, M.1, Miceli, T.1, Bergsagel, L.2, Hayman, S.1,
Reeder, C.2, Stewart, K.2, Dispenzieri, A.1, Gastineau, D.1,
Winters, J.3 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Scottsdale,
AZ; 3Mayo Clinic, Rochester, MN
Background: Patients with myeloma receiving initial therapy with
lenalidomide-based regimens can have difficulty collecting adequate
stem cells. Stem cell collection can be enhanced by the CXCR-4
antagonist plerixafor. Plerixafor is typically given subcutaneously
(SQ), with collection approximately 11 hours after injection to obtain
maximum yield. Intravenous administration can potentially allow
more rapid and predictable mobilization compared to the SQ route.
Patients and Methods: Patients receiving initial therapy with
a lenalidomide-based regimen and undergoing stem cell collection
within 12 months of myeloma diagnosis were enrolled. Patients
received GCSF at 10 mg/kg/day for 4 days followed by addition of
plerixafor at 0.24 mg/kg/dose starting on day 5. Plerixafor was
administered IV early morning (6-7 am) followed by apheresis be-
ginning 4-5 hours later; for a maximum of 5 days. The aims of the
study were to determine the proportion of patients reaching a stem
cell yield of at least 3 million CD34 cells/kg by second day of apher-
esis, the safety and tolerability of IV plerixafor, and the overall rate of
failure to mobilize (defined as\ 2.5 million CD34 cells/kg).
Results: Thirty-seven patients were accrued between December
2009 – April 2011, and 36 were eligible for analysis. The median
age was 61 years (range; 28-73); 61% were male. The median time
from start of initial therapy to enrollment was 4.6 months (range;
2.6 to 11.1) and the median cycles of lenalidomide were 4 (range;
3-11). Thirty-four (94%) of the patients achieved at least 3 millionCD34 cells/kg within 2 days of apheresis. The median CD34 cells/
kg after 1 day of collection was 3.9 million (range; 0.7 to 9.2) and af-
ter two days of collection was 7.02million (range: 1.1-16.5). Two pa-
tients failed the mobilization (\2.5 million CD34 cells/kg). There
were no grade 3 or 4 non-hematological adverse events and one pa-
tient experienced grade 4 thrombocytopenia. The most common
grade 1 or 2 adverse events seen were gastrointestinal, namely nau-
sea, diarrhea and abdominal pain or bloating. Grade 1 dizziness
was reported in 8 patients.
Conclusion: IV plerixafor is an effective strategy for mobilization in
this patient group with low rate of failure to mobilize. It is well tol-
erated with toxicity comparable to the SQ administration. It also of-
fers flexibility in patient scheduling with a convenient schedule for
early morning infusion followed by apheresis later in the day.
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THE EFFECTIVENESS AND COST EFFECTIVENESS OF PLERIXAFOR + GCSF
VERSUS GCSF 6 CHEMOTHERAPY AS SALVAGE MOBILIZATION REGI-
MENS IN LYMPHOMA AND MULTIPLE MYELOMA PATIENTS
Tuffaha, H.W., Hussein, A.A., Sharma, S., Abu-Jazar, H., Al-
Rawi, O.S., Saad, A.M., Al-Zaben, A., Hussein, N., Abdel-
Rahman, F.A. King Hussein Cancer Center, Amman, Jordan
Introduction: Plerixafor is a novel agent that enhances the mobili-
zation of peripheral blood stem cells (PBSCs) in lymphoma andmul-
tiple myeloma (MM) patients whose cells mobilize poorly. Due to
the substantial cost associated with its use, we aimed to compare
the effectiveness and cost effectiveness of Plerixafor + GCSF (PG)
versus GCSF 6 Chemotherapy (GC) as salvage mobilization regi-
mens at a stem cell transplant program in Jordan.
Methods: The charts of consecutive heavily pretreated lymphoma
and MM patients who had undergone at least one previous attempt
of PBSCs mobilization that failed or resulted in an insufficient cell
dose for transplant between 2007 and 2010 were retrospectively re-
viewed. Patients identified received salvage mobilization with GC
(prior to 2009) or PG after Plerixafor’s FDA-approval. Data collected
included demographics, medical histories, apheresis yields and trans-
plant outcome. Costs were calculated based on the JordanianMinistry
of Health list prices and included the costs of medications, apheresis,
hospital stay, and adverse effects management. Average cost effective-
ness ratio (ACER) was calculated by dividing the average cost of
PBSCs mobilization by the reported mobilization success rate.
Results: Seventeen patients were included, five received GC and
twelve received PG. A minimum CD34+ cell dose of $ 2 x 106
cells/kg was collected from 8 patients (67%) in the PG group com-
pared to 3 (60%) in the GC group. All patients successfully mobilized
with PG underwent autologous transplant compared to 2 (67%) mo-
bilized withGC.Therewas no difference inmedian days to neutrophil
or platelet engraftment between the two groups. PG was associated
with an average cost of $25,700 and ACER of $38,358/successful mo-
bilization compared to an average cost of $8,570 and ACER of
$14,283/successful mobilization for the GC group. (Table1)
Conclusion: Plerixafor as salvage treatment in this group of patients
showed an improved success rate of PBSCs mobilization and subse-
quent transplant but with a significant increase in cost. Prospective
comparative effectiveness and cost utility studies are warranted to in-
form the optimal salvage mobilization regimen. To our knowledge,
this is the first study from theMiddle East describing the use of Pler-
ixafor and the first with cost effectiveness data outside the US.
Table 1. Patient characteristics, mobilization outcome and
cost analysis
Salvage mobilization GCSF ± Plerixafor +regimen Chemotherapy (GC) GCSF (PG)No. of patients 5 12Average age (SD) 59 (3.7) 46 (12.4)Median CD34+
collected (106 cells/kg)2.1 3.9Patients Collected $ 2 x
106 cells/kg CD34+3 (60%) 8 (67%)Average mobilization cost $8,570 $25,700Average cost effectiveness
ratio (ACER)$14,283/successful
mobilization$38,358/successful
mobilization
